The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRAA), is offering the Fiscal Year 2024 Multiple Sclerosis Clinical Trial Award (MSRP CTA) to support innovative clinical trials aimed at improving the treatment and management of multiple sclerosis (MS). This grant opportunity invites applications for clinical trials that may range from small proof-of-concept studies to larger-scale trials, with funding levels set at $2 million for small trials (CTA-FL1) and up to $4 million for larger trials (CTA-FL2). The program emphasizes the importance of addressing the needs of military personnel and veterans, ensuring that proposed studies include diverse patient populations and demonstrate strong preliminary data. Interested applicants must submit a pre-application by June 10, 2024, followed by a full application due by October 7, 2024, with an estimated total program funding of $8 million available for approximately three awards. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.